Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Non-Current Debt (2018 - 2019)

X4 Pharmaceuticals (XFOR) has disclosed Non-Current Debt for 2 consecutive years, with $22.2 million as the latest value for Q2 2019.

  • For the quarter ending Q2 2019, Non-Current Debt rose 188.06% year-over-year to $22.2 million, compared with a TTM value of $22.2 million through Jun 2019, up 188.06%, and an annual FY2018 reading of $8.3 million, changed N/A over the prior year.
  • Non-Current Debt was $22.2 million for Q2 2019 at X4 Pharmaceuticals, up from $8.3 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $22.2 million in Q2 2019 and bottomed at $7.7 million in Q2 2018.